Quantcast

Latest Rare diseases Stories

2014-10-01 12:31:43

CINCINNATI, Oct. 1, 2014 /PRNewswire-USNewswire/ -- Researchers developed a new type of cell transplantation to treat mice mimicking a rare lung disease that one day could be used to treat this and other human lung diseases caused by dysfunctional immune cells. http://photos.prnewswire.com/prnvar/20110406/MM79025LOGO Scientists at Cincinnati Children's Hospital Medical Center report their findings in a study posted online Oct. 1 by Nature. In the study, the authors used macrophages,...

2014-10-01 08:33:29

New organization named the EB Research Partnership NEW YORK, Oct. 1, 2014 /PRNewswire/ -- The Jackson Gabriel Silver Foundation and Heal EB announced today a merger of their organizations to form the EB Research Partnership (EBRP), creating the largest non-profit organization dedicated solely to funding research to cure Epidermolysis Bullosa (EB). http://photos.prnewswire.com/prnvar/20141001/149573 EB is a group of devastating life-threatening genetic skin disorders impacting...

2014-09-30 12:30:15

"Food for Thought" to Promote Education, Fundraising for Rare Brain Disease RADNOR, Pa., Sept. 30, 2014 /PRNewswire-USNewswire/ -- Supporters from throughout the U.S. will host events during the 2(nd) Annual "Food for Thought" campaign from October 5-12, with the goal of raising awareness about frontotemporal degeneration (FTD). FTD is an often-misdiagnosed, progressive neurodegenerative disease affecting 50,000 people in the United States, and is the leading cause of dementia in adults...

2014-09-30 08:32:34

CLEVELAND, Sept. 30, 2014 /PRNewswire/ -- Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has completed the enrollment of the post-approval study of its NeuRx DPS® System for ALS patients. The last patient needed to meet the FDA enrollment requirement was implanted over a month and a half ahead of schedule. The NeuRx DPS®, which is the only medical device approved by the FDA specifically for ALS patients, is a humanitarian device that obtained approval at...

2014-09-26 23:03:30

MarketOptimizer.org adds “PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022” to its store. Novel Therapies to Revitalize the Neuropathic Pain Treatment Market Landscape by 2022. Dallas, Texas (PRWEB) September 26, 2014 With seven promising neuropathic pain (NP) treatments expected to be launched in the coming years, the NP therapeutics market value - covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - is forecast to...

2014-09-23 23:13:56

In his new role, Philip plans to use his position on the Board to advance MSA awareness, educate health professionals and collaborate with other charities to make government funding available to MSA patients. Philip is already well known in the MSA community for his tireless campaign with Tim’s MSA Shoe, an iconic symbol of Multiple System Atrophy. Detroit MI (PRWEB) September 23, 2014 The Multiple System Atrophy Coalition, a growing nonprofit 501(c) 3 organization dedicated to...

2014-09-23 12:35:49

Employees and Families Raise Funds, Awareness at Annual Family Picnic WASHINGTON, Sept. 23, 2014 /PRNewswire/ -- MicroPact Inc., the global leader in Data-First(TM) Case Management and Business Process Management (BPM) software, is proud to do its part to help find a cure for ALS, commonly referred to as Lou Gehrig's disease, by taking part in the ALS Ice Bucket Challenge at the company's annual family picnic Sept. 6. Members of MicroPact's Senior Management Team joined dozens of...

2014-09-18 23:04:52

Beyond Batten Disease Foundation Delivers the Largest Investment in the History of Batten Research to Texas Children’s Hospital Houston, TX (PRWEB) September 18, 2014 No treatment. No cure. Fatal. That’s what the parents of six-year old Will Herndon of The Woodlands were told when their son was diagnosed with a disorder that strikes young, otherwise healthy children. Will, now eleven, is blind and the family is heartbroken, but driven to find a cure. They are speaking for the first...

2014-09-18 16:28:15

- Data suggest support for potential label expansion of XIAFLEX for Dupuytren's contracture to include treatment of two affected joints concurrently; PDUFA date is October 20, 2014 - LYNBROOK, N.Y., Sept. 18, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced that positive...

2014-09-18 08:28:56

Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution of...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin